US EditionPublished • loading... • Updated
Akeso Reports Full-Year 2025 Financial Results
Akeso's 2025 sales rose 51.48% to RMB3.03 billion, driven by expanded bispecific immuno-oncology therapies and multiple new National Reimbursement Drug List indications.
- On Thursday, Akeso, Inc. reported 2025 annual results, achieving over 50% sales revenue growth driven by strong clinical validation and widespread adoption of its bispecific antibody portfolio.
- Akeso solidified its global leadership by advancing the "IO 2.0" strategy, anchoring commercial success on ivonescimab and cadonilimab, both now included in China's National Reimbursement Drug List .
- The company's global development program encompasses 15 Phase III trials, with ivonescimab benefiting approximately 70,000 patients to date while Akeso works on a pipeline of over 50 innovative assets.
- By embedding AI-powered R&D end-to-end, Akeso is expanding into "ADC 2.0" and trispecific platforms, extending therapeutic reach beyond oncology into immunology, respiratory, and CNS diseases.
- With stable pricing for core first-line indications and improved hospital access, Akeso's commercial platform is positioned for a transformative 2026, advancing over ten products in international trials.
Insights by Ground AI
59 Articles
59 Articles
InsideNoVA.com+56 Reposted by 56 other sources
Akeso Reports Full-Year 2025 Financial Results
HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business.
Table of contents: 1. TITLE PAGE 2. SELECTED FINANCIAL DATA 3. REPORT CORRECTION 4. REPORT CONTENTS attachments:2025_Annual_Financial_Report_of_Grupa_Kety_SA.xhtmlFinancial_Report2025_Annual_Financial_Report_of_Grupa_Kety_SA.xhtml.xadesFinancial_Report_signatureManagement_Report_of_Grupa_Kety_SA_2025.xhtmlManagement_Report_on_ActivitiesManagement_Report_of_Grupa_Kety_SA_2025.xhtml.xadesManagement_Report_on_Activities_signature25_GK_Report_on_Exa…
Coverage Details
Total News Sources59
Leaning Left7Leaning Right7Center21Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 20%
C 60%
R 20%
Factuality
To view factuality data please Upgrade to Premium
